|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003442,
umls-concept:C0006463,
umls-concept:C0024299,
umls-concept:C0035647,
umls-concept:C0040739,
umls-concept:C0085669,
umls-concept:C0092801,
umls-concept:C0205179,
umls-concept:C0205269,
umls-concept:C0302350,
umls-concept:C1882454
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-4-11
|
|
pubmed:abstractText |
Cladribine (2-CdA) is a purine analogue that exhibits activity against a variety of hematological malignancies and has a potent immunosuppressive effect. We therefore performed a pilot study to evaluate the feasibility of a novel 2-CdA-based reduced-intensity stem cell transplantation (RIST) regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:KamiMasahiroM,
pubmed-author:KanaiSachiyoS,
pubmed-author:KandaYoshinobuY,
pubmed-author:KatoKazunoriK,
pubmed-author:KawanoYoshifumiY,
pubmed-author:MakimotoAtsushiA,
pubmed-author:MatsubaraHiroshiH,
pubmed-author:MineishiShinS,
pubmed-author:NakaiKunihisaK,
pubmed-author:OgasawaraToshieT,
pubmed-author:OhnishiToshihiroT,
pubmed-author:SaitoTakeshiT,
pubmed-author:ShojiNahokoN,
pubmed-author:TakaueYoichiY,
pubmed-author:TanosakiRyujiR,
pubmed-author:TobinaiKenseiK,
pubmed-author:WakasugiHiroH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1014-20
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11948108-Adolescent,
pubmed-meshheading:11948108-Adult,
pubmed-meshheading:11948108-Aged,
pubmed-meshheading:11948108-Antilymphocyte Serum,
pubmed-meshheading:11948108-Busulfan,
pubmed-meshheading:11948108-Cladribine,
pubmed-meshheading:11948108-Combined Modality Therapy,
pubmed-meshheading:11948108-Graft vs Host Disease,
pubmed-meshheading:11948108-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11948108-Humans,
pubmed-meshheading:11948108-Immunosuppressive Agents,
pubmed-meshheading:11948108-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:11948108-Leukemia, Myeloid, Acute,
pubmed-meshheading:11948108-Middle Aged,
pubmed-meshheading:11948108-Myelodysplastic Syndromes,
pubmed-meshheading:11948108-Pilot Projects,
pubmed-meshheading:11948108-Staphylococcal Infections,
pubmed-meshheading:11948108-Survival Analysis,
pubmed-meshheading:11948108-Transplantation, Homologous,
pubmed-meshheading:11948108-Transplantation Chimera,
pubmed-meshheading:11948108-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
|
|
pubmed:affiliation |
Hematopoietic Stem Cell Transplantation and Hematology Division, National Cancer Center Hospital, Tokyo 104-0045, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
